Literature DB >> 1884104

Differential effects of (+/-)-dobutamine and human alpha-CGRP on cardiac and on regional haemodynamics in conscious Long Evans rats.

S M Gardiner1, A M Compton, P A Kemp, T Bennett, B Hughes, R Foulkes.   

Abstract

1. Comparisons were made of the full haemodynamic profiles of the known cardiostimulant, (+/-)-dobutamine, and the putative inotropic peptide, human alpha-calcitonin gene-related peptide (human alpha-CGRP), in conscious, chronically-instrumented Long Evans rats. Both substances were administered continuously i.v. for 60 min at two doses ((+/-)-dobutamine, 2 and 10 mumol kg-1 h-1; human alpha-CGRP, 0.15 and 1.5 nmol kg-1 h-1). 2. In spite of their similar (small) effects on mean arterial blood pressure, the low doses of (+/-)-dobutamine and human alpha-CGRP influenced cardiac haemodynamics differently. Thus, (+/-)-dobutamine caused an increase in cardiac index (due to a tachycardia), accompanied by rises in peak aortic flow, maximum rate of rise of aortic flow (dF/dtmax) and total peripheral conductance. However, the latter waned during the infusion, and after the infusion there was a significant systemic vasoconstriction and reductions in peak aortic flow, dF/dtmax and stroke index. Such 'off' effects following dobutamine infusion have not been described previously. The infusion of the lower dose of human alpha-CGRP caused only a transient fall in central venous pressure. 3. The rise in total peripheral conductance during infusion of the lower dose of (+/-)-dobutamine was associated with increases in hindquarters and common and internal carotid vascular conductances. The fall in total peripheral conductance after infusion was associated with renal vasoconstriction. Although there was no significant change in total peripheral conductance during the infusion of the lower dose of human alpha-CGRP there were hindquarters and carotid vasodilatations together with mesenteric vasoconstriction. 4. Infusion of the higher dose of ( )-dobutamine had greater effects than the lower dose on all cardiac haemodynamic variables and additionally, increased stroke index. However, the negative cardiac haemodynamic effects following the offset of infusion were also enhanced in association with marked renal and mesenteric vasoconstrictions. While infusion of the higher dose of human alpha-CGRP increased cardiac index, peak aortic flow, dF/dtmax and total peripheral conductance, stroke index fell together with central venous pressure. 5. (+/-)-Dobutamine caused greater cardiostimulation and increases in hindquarters blood flow than did human alpha-CGRP. However, the latter at the higher dose caused substantially greater common and internal carotid hyperaemia than did (+/-)-dobutamine, possibly indicating a selective and additional effect of human alpha-CGRP on cranial blood flow. Furthermore, there were no adverse cardiovascular effects following infusion of human alpha-CGRP.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1884104      PMCID: PMC1908385          DOI: 10.1111/j.1476-5381.1991.tb09817.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  37 in total

1.  Regional and cardiac haemodynamic effects of NG-nitro-L-arginine methyl ester in conscious, Long Evans rats.

Authors:  S M Gardiner; A M Compton; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

2.  Regional hemodynamic responses to adrenoceptor antagonism in conscious rats.

Authors:  S M Gardiner; T Bennett
Journal:  Am J Physiol       Date:  1988-10

3.  Effects of dobutamine on left ventricular performance, coronary dynamics, and distribution of cardiac output in conscious dogs.

Authors:  S F Vatner; R J McRitchie; E Braunwald
Journal:  J Clin Invest       Date:  1974-05       Impact factor: 14.808

4.  Human calcitonin gene-related peptide activates adenylate cyclase and releases prostacyclin from human umbilical vein endothelial cells.

Authors:  D Crossman; J McEwan; J MacDermot; I MacIntyre; C T Dollery
Journal:  Br J Pharmacol       Date:  1987-12       Impact factor: 8.739

5.  Systemic hemodynamic effects of dopamine, (+/-)-dobutamine and the (+)-and (-)-enantiomers of dobutamine in anesthetized normotensive rats.

Authors:  R R Ruffolo; K Messick
Journal:  Eur J Pharmacol       Date:  1985-02-26       Impact factor: 4.432

6.  Calcitonin gene-related peptide is a stimulator of renin secretion.

Authors:  A Kurtz; R Muff; W Born; J M Lundberg; B I Millberg; M P Gnädinger; D E Uehlinger; P Weidmann; T Hökfelt; J A Fischer
Journal:  J Clin Invest       Date:  1988-08       Impact factor: 14.808

7.  Inotropic selectivity of dobutamine enantiomers in the pithed rat.

Authors:  R R Ruffolo; K Messick
Journal:  J Pharmacol Exp Ther       Date:  1985-11       Impact factor: 4.030

8.  Changes in regional blood flow distribution induced by infusions of dopexamine hydrochloride or dobutamine in anesthetized dogs.

Authors:  G P Biro; J R Douglas; W J Keon; G C Taichman
Journal:  Am J Cardiol       Date:  1988-08-11       Impact factor: 2.778

9.  Inotropic, vascular and neuroendocrine effects of dopexamine hydrochloride and comparison with dobutamine.

Authors:  B E Jaski; C Peters
Journal:  Am J Cardiol       Date:  1988-08-11       Impact factor: 2.778

10.  Central and regional vascular hemodynamics following intravenous milrinone in the conscious rat: comparison with dobutamine.

Authors:  H Drexler; S Höing; F Faude; H Wollschläger; H Just
Journal:  J Cardiovasc Pharmacol       Date:  1987-05       Impact factor: 3.105

View more
  3 in total

1.  Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats.

Authors:  S M Gardiner; J E March; P A Kemp; J J Mullins; T Bennett
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

2.  Effects of chronic infusions of alpha-trinositol on regional and cardiac haemodynamics in conscious rats.

Authors:  S M Gardiner; P A Kemp; B Fallgren; T Bennett
Journal:  Br J Pharmacol       Date:  1994-09       Impact factor: 8.739

3.  Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist.

Authors:  Aimee L Brame; Janet J Maguire; Peiran Yang; Alex Dyson; Rubben Torella; Joseph Cheriyan; Mervyn Singer; Robert C Glen; Ian B Wilkinson; Anthony P Davenport
Journal:  Hypertension       Date:  2015-02-23       Impact factor: 10.190

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.